Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2022

View Archived Issues

PLK4 inhibitor with promising preclinical activity against TRIM37-amplified breast cancer

Murine model resembles cardiovascular disease seen in NAFLD

Medshine Discovery patents compounds for fungal infections

Chiesi Farmaceutici discloses new ROCK inhibitors

UCB SA divulges new DRD1 PAMs

Roche presents new Raf kinase B inhibitors

Chengdu Baiyu Pharmaceutical identifies new LANCL2 activators

SBP-101 modulates polyamine metabolism and shows efficacy in ovarian cancer models

Novel murine models of diet-induced NASH developed

RS BioTherapeutics reports findings on RSBT-001 in mouse model of pulmonary inflammation

MIF/CD74 axis identified as a critical determinant of TME composition in sarcoma

iNtRON Biotechnology reports efficacy of CDL-200 against clinical isolates from CDI patients

PARP/SIK2 inhibition shows potential for treating ovarian cancer and TNBC

Tenaya sets out rationale for targeting HDAC6 in heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...